Secretory TRAIL-Armed Natural Killer Cell–Based Therapy: In Vitro and In Vivo Colorectal Peritoneal Carcinomatosis Xenograft

Since its discovery in 1995, TNF-related apoptosis-inducing ligand (TRAIL) has sparked growing interest among oncologists due to its remarkable ability to induce apoptosis in malignant human cells, but not in most normal cells. However, one major drawback is its fast clearance rate in vivo. Thus, the development of an alternative means of delivery may increase the effectiveness of TRAIL-based therapy. In this study, we developed a secretory TRAIL-armed natural killer (NK) cell–based therapy and assessed its cytotoxic effects on colorectal cancer cells and its tumoricidal efficacy on colorectal peritoneal carcinomatosis xenograft. We generated genetically modified NK cells by transduction with a lentiviral vector consisting of a secretion signal domain, a trimerization domain, and an extracellular domain of the TRAIL gene. These NK cells secreted a glycosylated form of TRAIL fusion protein that induced apoptotic death. Intraperitoneally, but not intravenously, injected NK cells effectively accumulated at tumor sites, infiltrated tumor tissue, induced apoptosis, and delayed tumor growth. These results shed light on the therapeutic potential of genetically engineered NK cells to treat peritoneal carcinomatosis. Mol Cancer Ther; 15(7); 1591–601. ©2016 AACR.

[1]  C. Viswanathan,et al.  Natural killer cells: In health and disease. , 2015, Hematology/oncology and stem cell therapy.

[2]  A. Makrigiannis,et al.  Ly49 family receptors are required for cancer immunosurveillance mediated by natural killer cells. , 2014, Cancer research.

[3]  H. Ljunggren,et al.  Immunomodulatory activity of commonly used drugs on Fc-receptor-mediated human natural killer cell activation , 2014, Cancer Immunology, Immunotherapy.

[4]  A. Moretta,et al.  TLR/NCR/KIR: Which One to Use and When? , 2014, Front. Immunol..

[5]  V. Kuchroo,et al.  Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade , 2014, Cancer Immunology Research.

[6]  Haizhen Wang,et al.  Immunoglobulin Fc Domain Fusion to TRAIL Significantly Prolongs Its Plasma Half-Life and Enhances Its Antitumor Activity , 2014, Molecular Cancer Therapeutics.

[7]  G. Berchem,et al.  The Critical Role of the Tumor Microenvironment in Shaping Natural Killer Cell-Mediated Anti-Tumor Immunity , 2013, Front. Immunol..

[8]  X. Song,et al.  Hyperthermia enhances mapatumumab-induced apoptotic death through ubiquitin-mediated degradation of cellular FLIP(long) in human colon cancer cells , 2013, Cell Death and Disease.

[9]  Sumati Rajagopalan,et al.  Controlling natural killer cell responses: integration of signals for activation and inhibition. , 2013, Annual review of immunology.

[10]  Yong J. Lee,et al.  The Role of Bcl-xL in Synergistic Induction of Apoptosis by Mapatumumab and Oxaliplatin in Combination with Hyperthermia on Human Colon Cancer , 2012, Molecular Cancer Research.

[11]  P. Wintrode,et al.  Effects of glycosylation on the stability and flexibility of a metastable protein: the human serpin α(1)-antitrypsin. , 2011, International journal of mass spectrometry.

[12]  Per Albertsson,et al.  Matrix Metalloproteinases in Cytotoxic Lymphocytes Impact on Tumour Infiltration and Immunomodulation , 2010, Cancer Microenvironment.

[13]  M. Caligiuri,et al.  The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. , 2010, Blood.

[14]  M. T. Dorak,et al.  A study of natural killer cell lectin-like receptor K1 gene (KLRK1/NKG2D) region polymorphisms in a European population sample. , 2009, Tissue antigens.

[15]  F. Takei,et al.  A Dual Role for Talin in NK Cell Cytotoxicity: Activation of LFA-1-Mediated Cell Adhesion and Polarization of NK Cells1 , 2009, The Journal of Immunology.

[16]  M. Yazawa,et al.  A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  R. Herbst,et al.  Population pharmacokinetic (PPK) analysis of recombinant human Apo2L/TRAIL (rhApo2L/TRAIL) in a Phase 1a Study in advanced cancer and lymphoma , 2008 .

[18]  Eric Vivier,et al.  Functions of natural killer cells , 2008, Nature Immunology.

[19]  H. Ljunggren,et al.  NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy , 2008, Cancer Immunology, Immunotherapy.

[20]  K. B. Knudsen,et al.  Cytokine gene therapy using adenovirally transduced, tumor-seeking activated natural killer cells. , 2007, Human gene therapy.

[21]  P. Basse,et al.  Targeting of products of genes to tumor sites using adoptively transferred A-NK and T-LAK cells , 2007, Cancer Gene Therapy.

[22]  L. Frati,et al.  High-efficient lentiviral vector-mediated gene transfer into primary human NK cells. , 2006, Experimental hematology.

[23]  R. Herbst,et al.  Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  L. Zitvogel,et al.  Natural-killer cells and dendritic cells: "l'union fait la force". , 2005, Blood.

[25]  H. Klingemann.  Natural killer cell-based immunotherapeutic strategies. , 2005, Cytotherapy.

[26]  W. Yokoyama,et al.  The dynamic life of natural killer cells. , 2004, Annual review of immunology.

[27]  Simon C Watkins,et al.  Tumor‐localization by adoptively transferred, interleukin‐2‐activated NK cells leads to destruction of well‐established lung metastases , 2003, International journal of cancer.

[28]  K. Totpal,et al.  Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. , 2001, The Journal of pharmacology and experimental therapeutics.

[29]  E. Seifried,et al.  Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. , 2001, Journal of hematotherapy & stem cell research.

[30]  Z. Wang,et al.  Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity , 2001, Nature Medicine.

[31]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[32]  E. Alnemri,et al.  Natural Killer (NK) Cell–mediated Cytotoxicity: Differential Use of  TRAIL and Fas Ligand by Immature and Mature Primary Human NK Cells , 1998, The Journal of experimental medicine.

[33]  T. Whiteside,et al.  The role of natural killer cells in immune surveillance of cancer. , 1995, Current opinion in immunology.

[34]  J. Gong,et al.  Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. , 1994, Leukemia.

[35]  J. R. Oehler,et al.  Natural cell‐mediated cytotoxicity in rats. III. Effects of immunopharmacologic treatments on natural reactivity and on reactivity augmented by polyinosinic‐polycytidylic acid , 1978, International journal of cancer.

[36]  H. Kirchner,et al.  Cell-mediated immunity to leukemia virus- and tumor-associated antigens in mice. , 1976, Cancer research.

[37]  L. Downs,et al.  A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. , 2011, Cytotherapy.

[38]  P. Kuppen,et al.  Interleukin-2 activated NK cells do not use the CD95L- and TRAIL-pathways in the rapid induction of apoptosis of rat colon carcinoma CC531s cells. , 2003, Immunobiology.

[39]  Lewis L Lanier,et al.  Natural killer cells and cancer. , 2003, Advances in cancer research.

[40]  R. Herberman,et al.  Natural cell-mediated immunity. , 1978, Advances in cancer research.